Oncogenic proteins as tumor antigens.
Human immune responses to oncogenic proteins have been reported and are continuing to be defined. Immunity to nonmutated overexpressed oncoproteins as well as to mutated or unique cancer-specific oncoproteins has been identified. Immune system based treatments targeting oncogenic proteins have shown therapeutic efficacy in animals models and are currently being translated into human clinical trials.
University of Washington, Division of Oncology, Seattle 98195-6527, USA. ndisis@u.washington.edu
M L
ML
Disis
M A
MA
Cheever
D000818:Animals; D000951:Antigens, Neoplasm / Q000235:genetics; D019496:Cancer Vaccines / Q000494:pharmacology; D015870:Gene Expression; D006801:Humans; D009154:Mutation; D009363:Neoplasm Proteins / Q000235:genetics / Q000276:immunology*; D009369:Neoplasms / Q000235:genetics / Q000276:immunology / Q000628:therapy; D009857:Oncogenes; D014178:Translocation, Genetic
D000951:Antigens, Neoplasm; D019496:Cancer Vaccines; D009363:Neoplasm Proteins